EA201891752A3 - Фармацевтическая композиция для улучшения состояния при хронической почечной недостаточности или предотвращения ее прогрессирования - Google Patents

Фармацевтическая композиция для улучшения состояния при хронической почечной недостаточности или предотвращения ее прогрессирования

Info

Publication number
EA201891752A3
EA201891752A3 EA201891752A EA201891752A EA201891752A3 EA 201891752 A3 EA201891752 A3 EA 201891752A3 EA 201891752 A EA201891752 A EA 201891752A EA 201891752 A EA201891752 A EA 201891752A EA 201891752 A3 EA201891752 A3 EA 201891752A3
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
chronic renal
progression
prevent
condition during
Prior art date
Application number
EA201891752A
Other languages
English (en)
Other versions
EA201891752A2 (ru
EA035709B1 (ru
Inventor
Анкит Шиам Сингх
Ведпракаш Мишра
Неелима Тонгра
Original Assignee
Фримлайн Прайвет Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фримлайн Прайвет Лимитед filed Critical Фримлайн Прайвет Лимитед
Publication of EA201891752A2 publication Critical patent/EA201891752A2/ru
Publication of EA201891752A3 publication Critical patent/EA201891752A3/ru
Publication of EA035709B1 publication Critical patent/EA035709B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящая заявка относится к фармацевтической композиции/составу для улучшения состояния при хронической почечной недостаточности (ХПН), вызванной воспалением и/или недостаточной экспрессией клото, или предотвращения ее развития. Более конкретно, настоящее изобретение относится к композиции/составу, содержащему синергическую комбинацию пальмитоилэтаноламида (ПЭА), холекальциферола и одного или нескольких природных ингредиентов. Настоящее изобретение также обеспечивает различные составы и способы их получения.
EA201891752A 2017-09-05 2018-08-31 Фармацевтическая композиция для улучшения состояния при хронической почечной недостаточности или предотвращения ее прогрессирования EA035709B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201721031443 2017-09-05

Publications (3)

Publication Number Publication Date
EA201891752A2 EA201891752A2 (ru) 2019-03-29
EA201891752A3 true EA201891752A3 (ru) 2019-05-31
EA035709B1 EA035709B1 (ru) 2020-07-29

Family

ID=63490286

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891752A EA035709B1 (ru) 2017-09-05 2018-08-31 Фармацевтическая композиция для улучшения состояния при хронической почечной недостаточности или предотвращения ее прогрессирования

Country Status (8)

Country Link
US (1) US10973782B2 (ru)
EP (1) EP3449943B1 (ru)
CA (1) CA3015399C (ru)
EA (1) EA035709B1 (ru)
MY (1) MY186286A (ru)
PH (1) PH12018000227B1 (ru)
SG (1) SG10201807034XA (ru)
UA (1) UA123448C2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11523998B2 (en) 2018-06-14 2022-12-13 The Texas A&M University System Anti-inflammatory formulations and uses thereof including a combination of palmitoylethanolamide and plant-based polyphenols
WO2020141546A1 (en) * 2019-01-02 2020-07-09 Celagenex Research (India) Pvt. Ltd. Synergistic nutritional compositions for pain management
CN115697307A (zh) * 2020-06-19 2023-02-03 葛兰素史密斯克莱知识产权（第2 号）有限公司 包含达普司他的制剂

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506224A (en) 1991-12-31 1996-04-09 Lifegroup S.P.A. N-acyl derivatives of aminoalcohols active as local autacoids and useful in the therapy of autoimmune processes
IT1271266B (it) 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
CA2330681C (en) 1998-05-29 2008-08-26 Andrea Giuffrida Control of pain with endogenous cannabinoids
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
KR20030087657A (ko) 2001-03-27 2003-11-14 더 리전츠 오브 더 유니버시티 오브 캘리포니아 체지방 감소 및 지방산 대사 조절을 위한 방법, 화합물 및조성물
JP2007509066A (ja) 2003-10-16 2007-04-12 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 体脂肪を減らし、食欲を抑制し、脂肪酸代謝を調節するための食物および他の組成物、化合物ならびに方法
ITPD20050224A1 (it) * 2005-07-19 2007-01-20 Actimex Srl Composizioni contenenti micronutrienti aventi in particolare attivita' antiossidante e loro impiego
US20070207225A1 (en) * 2006-03-03 2007-09-06 Francesco Squadrito Genistein modulated reduction of cardiovascular risk factors
DE602006013787D1 (de) 2006-03-28 2010-06-02 Epitech Group Srl Eine Pharmazeutische Zusammensetzung zur Behandlung von Pathologien, die durch die allgemeine Immunantwort verursacht werden
US8680053B2 (en) * 2008-07-09 2014-03-25 Quercegen Pharmaceuticals Llc Improving renal function with quercetin-containing compositions
ES2377869T3 (es) * 2008-09-04 2012-04-02 Cargill, Incorporated Fabricación de comprimidos de eritritol
ES2548190T3 (es) 2009-09-07 2015-10-14 Epitech Group S.P.A. Composición que contiene palmitoiletanolamida ultramicronizada
JP2013508338A (ja) * 2009-10-20 2013-03-07 ヘルボニス アクチェンゲゼルシャフト 骨代謝障害および腎障害の治療を目的としたＳａｌｏｎｕｍＧｌａｕｃｏｐｈｙｌｌｕｍ由来エキスの使用
EP2598477B1 (en) 2010-07-28 2016-03-02 The Regents of The University of California Peripherally restricted faah inhibitors
EP2444078B1 (en) * 2010-10-04 2017-09-13 EPITECH GROUP S.p.A. Use of amides of mono and dicarboxylic acids in the treatment of renal diseases
JP6092870B2 (ja) 2011-08-19 2017-03-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア メタ置換ビフェニル末梢に限局されたｆａａｈ阻害剤
US20130085121A1 (en) * 2011-09-30 2013-04-04 Jianguo Wang Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d
CN104244948B (zh) * 2012-02-17 2016-11-16 爱普泰克集团有限公司 在炎症性疾病的治疗中使用的用于调节n-酰基乙醇胺的特异性酰胺酶的组合物和方法
WO2014004676A1 (en) * 2012-06-26 2014-01-03 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors as neuroprotective agents in the cns
CA2879726A1 (en) 2012-07-24 2014-01-30 Bial- Portela & Ca, S.A. Urea compounds and their use as enzyme inhibitors
NL2011448C2 (en) 2012-09-17 2015-01-29 Jp Russell Science Holding Ltd Pharmaceutical or neutraceutical composition comprising palmitoylethanolamide particles.
WO2014202956A1 (en) * 2013-06-21 2014-12-24 Noakes, David Vitamin d complexes with de-vdbp and an unsaturated fatty acid, and their use in therapy
ITMI20131180A1 (it) 2013-07-15 2015-01-16 Fond Istituto Italiano Di Tecnologia O-alchil triazolil carbammati come inibitori di idrolasi delle ammidi degli acidi grassi (faah)
EP3022179B1 (en) 2013-07-18 2017-11-15 Fondazione Istituto Italiano Di Tecnologia Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (faah) enzyme and modulators of the d3 dopamine receptor (d3dr)
WO2015012708A1 (en) 2013-07-24 2015-01-29 BIAL - PORTELA & Cª, S.A. Imidazolecarboxamides and their use as faah inhibitors
CN105593226A (zh) 2013-08-01 2016-05-18 比亚尔-珀特拉和Ca股份公司 脲类化合物及其作为faah酶抑制剂的用途
ES2603809T3 (es) * 2014-03-19 2017-03-01 Epitech Group S.R.L. Composición farmacéutica que comprende palmitoiletanolamida y L-acetilcarnitina
ES2908240T3 (es) 2014-04-07 2022-04-28 Univ California Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos
TR201908936T4 (tr) 2014-05-14 2019-07-22 Epitech Group S P A Opioidler ile kombinasyon halinde palmitoiletanolamid kullanımı.
DK3215143T3 (da) 2014-10-22 2021-09-20 Again Life Italia Srl Kombination omfattende spirulina og palmitoylethanolamid
NL2014464B1 (en) 2015-03-16 2017-01-13 Vanderbilt Science Holding Ltd Composition for use in the treatment of neuropathic pain.
WO2016183134A1 (en) 2015-05-12 2016-11-17 Cutting Edge Medical Solutions, Llc Palmitoylethanolamide compositions
JP7244992B2 (ja) 2015-05-21 2023-03-23 エスシーアイ スパーク リミティド オピオイドとｎ－アシルエタノールアミンの組み合わせ
EP3302451B1 (en) 2015-06-04 2023-09-06 Ali Research S.R.L. Combination comprising palmitoylethanolamide (pea) and lycopene for use in the treatment of inflammatory diseases
ITUB20153066A1 (it) * 2015-08-11 2017-02-11 Graal S R L Composizione alimentare e/o nutraceutica contenente pea

Also Published As

Publication number Publication date
EP3449943B1 (en) 2022-08-31
MY186286A (en) 2021-07-05
US10973782B2 (en) 2021-04-13
BR102018067846A2 (pt) 2020-07-07
US20190070133A1 (en) 2019-03-07
CA3015399A1 (en) 2019-03-05
SG10201807034XA (en) 2019-04-29
EA201891752A2 (ru) 2019-03-29
UA123448C2 (uk) 2021-04-07
CA3015399C (en) 2020-03-24
PH12018000227A1 (en) 2019-03-11
EP3449943A1 (en) 2019-03-06
EA035709B1 (ru) 2020-07-29
PH12018000227B1 (en) 2019-03-11

Similar Documents

Publication Publication Date Title
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
MX2022003757A (es) Composiciones para el cuidado bucal con actividad anticaries.
BR112017016636A2 (pt) formulação líquida estável para anticorpos monoclonais
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
AR104835A1 (es) Composiciones nutricionales que contienen un nivel elevado de inositol y uso de las mismas
BR112015015870A8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
BR112019018088A2 (pt) Composições propositadamente selecionadas que compreendem canabinoides purificados e/ou terpenos purificados
CO2021014260A2 (es) Formas sólidas de un inhibidor de glyt1
PE20160010A1 (es) Composicion nutricional de la anti regurgitacion
EA201891752A2 (ru) Фармацевтическая композиция для улучшения состояния при хронической почечной недостаточности или предотвращения ее прогрессирования
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
MX388970B (es) Formulaciones para estabilizar la humedad en alimentos musculares.
EA201791716A1 (ru) Фармацевтический состав
EA202191345A1 (ru) Стабильный состав глюкокортикоидов
BR112017016497A2 (pt) composições e métodos para metabolismo muscular melhorado
EA202090732A1 (ru) Составы для трансдермального введения
EA202090971A1 (ru) Способы применения и композиции, содержащие дулаглутид
JOP20190275B1 (ar) طرق وتركيبات لعلاج اضطراب إسهال خِلقي